Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of May 31st, 2024

Regulatory News:

Median Technologies (Paris:ALMDT):

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering in innovative imaging solutions and services, MEDIAN TECHNOLOGIES harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240607247069/en/